The acute lymphoblastic leukemia (ALL) therapy market is growing steadily, fueled by innovations in the treatment paradigm. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Blincyto-based therapies, is impacting the disease’s treatment algorithm. Although multiagent chemotherapy remains the cornerstone of treatment, recently approved therapies (Amgen’s Blincyto and Pfizer’s Besponsa) have expanded the number of options available. CAR T-cell therapies (Novartis’s Kymriah and Kite Pharma’s Tecartus) have also expanded options in the relapse and refractory setting, offering patients additional support. The emerging therapy pipeline continues to grow with therapies such as AbbVie / Roche’s Venclexta / Venclyxto and Bristol Myers Squibb’s CAR T-cell therapy Breyanzi showing promising development. Nevertheless, clinical and commercial potential remains for ALL therapies with improved efficacy, a novel mechanism of action, and/or the ability to treat underserved patient segments, such as T-cell ALL.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.